Amylin Pharmaceuticals: Diabetes and Beyond
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time the company has a second drug, Byetta, in its pipeline. Graham must decide how to manage the company's limited resources while also finalizing another deal that has huge future potential. Graham knows that Amylin's immediate success depends on its ability to commercialize its products but its long-term success depends on replenishing its pipeline. Can the company do it all successfully?
Collection: HBSP (USA)
Ref: HBS-809011-E
Format: PDF
Number of pages: 19
Publication Date: Dec 9, 2008
Language: English
Review date: Oct 15, 2013
What material is included in this case:
Description
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time the company has a second drug, Byetta, in its pipeline. Graham must decide how to manage the company's limited resources while also finalizing another deal that has huge future potential. Graham knows that Amylin's immediate success depends on its ability to commercialize its products but its long-term success depends on replenishing its pipeline. Can the company do it all successfully?
Read more
Year: 2005
Geographic Setting: California
Industry Setting: Health care services; Pharmaceuticals; Regulation
Leave your rating
"Amylin Pharmaceuticals: Diabetes and Beyond"
Register for free with IESE Publishing and enjoy all the advantages
What type of account do you want to create?
Choose account type
Professors
Academic Institutions
Companies
Individuals